BIO-KEY International adjourned its annual meeting and will reconvene it on October 2 after stockholders lacked enough votes on issuing up to 1,236,668 common shares upon Warrant exercise. The delay gives stockholders more time to consider the warrant-related proposal, while previously submitted votes remain valid unless holders choose to change them.
Key Highlights
- A quorum attended BIO-KEY International’s annual meeting, but the warrant-related proposal lacked sufficient votes for approval.
- The meeting’s Record Date remains July 15, 2026.
- Stockholders who already voted and do not want to alter their choice need no further action.
BIO-KEY International Inc. (NASDAQ: BKYI) adjourned its 2026 annual meeting after stockholders did not have enough votes to approve issuance of up to 1,236,668 common shares upon exercise of warrants. The proposals remain unchanged.
Warrant Share Vote Moves to October 2
A quorum was present when the annual meeting convened on September 3, 2026. The proposal appeared in a supplement distributed after the original proxy statement, which was filed on July 24, 2026, and the supplement was filed on August 24, 2026. All polls remain open, and the record date continues to be July 15, 2026. BIO-KEY said no changes were made to the matters submitted for stockholder consideration.
Revised Proxies Required for Unvoted Shares
Stockholders who have not voted on the warrant-related measure must submit a new proxy using the revised proxy card previously distributed with the supplement, or vote through the available internet or telephone instructions. Holders who already submitted a proxy or otherwise voted do not need to act if they do not want to change their decision. BIO-KEY directed stockholders to review the proxy statement, supplement and other meeting materials before voting.
FAQs
Q: When will BIO-KEY International’s annual meeting reconvene?
A: BIO-KEY’s 2026 Annual Meeting will reconvene Friday, October 2, 2026, at 10:00 a.m. local time. It will be held at the Company’s offices at 101 Crawfords Corner Road, Suite 4116, Holmdel, New Jersey.
Q: Do BIO-KEY stockholders need to vote again?
A: Stockholders who have not voted on the warrant-related proposal must submit a new proxy. Those who already voted need no further action unless they want to change their vote.
Q: What does Proposal 4 concern?
A: Proposal 4 seeks stockholder approval under NASDAQ Listing Rule 5635(d) for issuing up to 1,236,668 common shares upon exercise of warrants issued in BIO-KEY’s August 10, 2026 warrant inducement transaction. The proposal was not approved at the initial meeting.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.